---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-038072"
form_type: "8-K"
ticker: "PAVM"
cik: "0001624326"
company_name: "PAVmed Inc."
filed_at: "2026-08-14T14:44:53+00:00"
generated_at: "2026-08-14T14:45:38.283664+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# PAVmed Q2 2026 net loss $5.5M; Lucid EsoGuard revenue $1.5M, cash up to $3.8M

## Summary
- Q2 2026 GAAP net loss ~$5.5M ($0.87/diluted share); non-GAAP adjusted net loss ~$1.7M ($0.27/share).
- Cash and equivalents $3.8M at June 30, 2026, up from $1.5M at Dec 31, 2025; operating expenses ~$7.1M.
- Lucid Diagnostics (LUCD) posted $1.5M EsoGuard revenue in 2Q26, 2,770 tests; secured first lab benefit manager coverage policy.
- Veris Health accelerated commercial engagement with OSU-The James; implantable monitor on track for early 2027 FDA 510(k) submission.
- PortIO first-in-human data published in Journal of Vascular Access: 100% patency, 90% intended implant duration completion, no device-related adverse events.

## SEC filing metadata
- accession: 0001493152-26-038072
- form_type: 8-K
- ticker: PAVM
- cik: 0001624326
- company_name: PAVmed Inc.
- filed_at: 2026-08-14T14:44:53+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1624326/000149315226038072/0001493152-26-038072-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1624326/000149315226038072/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-038072
- JSON: https://secwatch.observer/filing/0001493152-26-038072.json
- Plain text: https://secwatch.observer/filing/0001493152-26-038072.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.